Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

BACKGROUND The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy for most patients, who have a midrange score. METHODS We performed a prospective trial involving 10,273 women with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer. Of the 9719 eligible patients with follow-up information, 6711 (69%) had a midrange recurrence score of 11 to 25 and were randomly assigned to receive either chemoendocrine therapy or endocrine therapy alone. The trial was designed to show noninferiority of endocrine therapy alone for invasive disease–free survival (defined as freedom from invasive disease recurrence, second primary cancer, or death). RESULTS Endocrine therapy was noninferior to chemoendocrine therapy in the analysis of invasive disease–free survival (hazard ratio for invasive disease recurrence, second primary cancer, or death [endocrine vs. chemoendocrine therapy], 1.08; 95% confidence interval, 0.94 to 1.24; P=0.26). At 9 years, the two treatment groups had similar rates of invasive disease–free survival (83.3% in the endocrine-therapy group and 84.3% in the chemoendocrine-therapy group), freedom from disease recurrence at a distant site (94.5% and 95.0%) or at a distant or local–regional site (92.2% and 92.9%), and overall survival (93.9% and 93.8%). The chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age (P=0.004), with some benefit of chemotherapy found in women 50 years of age or younger with a recurrence score of 16 to 25. CONCLUSIONS Adjuvant endocrine therapy and chemoendocrine therapy had similar efficacy in women with hormone-receptor–positive, HER2-negative, axillary node–negative breast cancer who had a midrange 21-gene recurrence score, although some benefit of chemotherapy was found in some women 50 years of age or younger

Genome remodelling in a basal-like breast cancer metastasis and xenograft

Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples from an African-American patient with basal-like breast cancer: peripheral blood, the primary tumour, a brain metastasis and a xenograft derived from the primary tumour. The metastasis contained two de novo mutations and a large deletion not present in the primary tumour, and was significantly enriched for 20 shared mutations. The xenograft retained all primary tumour mutations and displayed a mutation enrichment pattern that resembled the metastasis. Two overlapping large deletions, encompassing CTNNA1, were present in all three tumour samples. The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour

Status reports to the Paper Properties and Uses Project Advisory Committee

"October 21-22, 1987."Board properties and performance: project 3571 / W. J. Whitsitt , R. A. Halcomb , J. Dess ; Process, properties, product relationships: project 3467 / G. A. Baum , C. C. Habeger ; Internal strength enhancement: project 3526 / R. Stratton , K. Hardacker ; Strength improvement and failure mechanisms / J. Waterhouse , W. Whitsitt ; On-line measurement of paper mechanical properties: project 3332 / C. C. Habeger , G. A. Baum , M. S. Hall

Status reports to the Paper Properties and Uses Project Advisory Committee

"October 19-20, 1988."Copy 2 includes slide material.Strength improvement and failure mechanisms: project 3469 / J. Waterhouse ; Internal strength enhancement: project 3526 / R. Stratton, K. Hardacker ; Fundamentals of paper surface wettability: project 3646 / F. Etzler, R. Stratton ; Board properties and performance: project 3571 / W.J. Whitsitt, R.A. Halcomb, J. Dees ; Process, properties, product relationships: project 3467 / C. Habeger, K. Hardacker, Y. Pan ; On-line measurement of paper mechanical properties: project 3332/3613 / C. C. Habeger, M. S. Hall -- Slide material

Status reports to the Paper Properties and Uses Project Advisory Committee

"March 22-23, 1989."Board properties and performance: project 3571 / W. J. Whitsitt , R. A. Halcomb , J. Dees ; Process, properties, product relationships: project 3467 / C. Habeger , K. Hardacker , Y. Pan ; Fundamentals of paper surface wettability: project 3646 / F. Etzler , R. Stratton ; On-line measurement of paper mechanical properties: project 3332/3613 / C. C. Habeger , M. S. Hall ; Internal strength enhancement: project 3526 / R. Stratton , K. Hardacker , D. Hollenberg ; Strength improvement and failure mechanisms: project 3469 / J. Waterhouse